Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 4 2Phase 3 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thrombosis 2Neoplasms 2Venous Thromboembolism 1Pulmonary Embolism 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × edoxaban × Clear all
NCT06149533 2023-11-29

Thrombosis

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3 Not yet recruiting
366 enrolled

Neoplasms, Venous Thrombosis

NCT02073682 2019-03-06

Cancer Venous Thromboembolism (VTE)

Daiichi Sankyo

Phase 3 Completed
1,046 enrolled 24 charts
Classical hematology

Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡